Disclosure Under Regulation 30 Of SEBI Listing Regulations
RoutineLowmateriality 24 out of 100
What happened
FactDisclosure Under Regulation 30 Of SEBI Listing Regulations.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Demand
WithdrawnEarlierQ4 FY26
We were told that it's a $5 billion, $6 billion, just the CDMO space, $5 billion, $6 billion market opportunity, and it has a very healthy CAGR as an industry because there's a lot of GLP-1s coming in.
NowQ4 FY26
I think we're in a similar kind of a situation with peptides where we believe it will grow.
Change
FactGuidance withdrawn
Implication
CapitSignal interpretationThe earlier statement provided specific figures for the market opportunity in the CDMO space, while the current statement does not provide any numeric target or specific market size, indicating a withdrawal of guidance.confidence 90%
Earlier statement · Q4 FY26Latest statement · Q4 FY26
Watch next
Fact- I think the 18% to 20% CAGR that we talked about is potential that we see. (management committed by FY27)
Evidence
- Neuland Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.(opens the original filing in a new tab)
- Earlier statement · Q4 FY26
- Latest statement · Q4 FY26
How CapitSignal classified this
- Reasoning:
- BOARD_MEETING base 22; +2 corroborating keywords; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%